Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in Maine: The Complete Guide for Women, Families, and Survivors
For women in Maine navigating the aftermath of a breast procedure, the realization that an implanted medical device may be causing systemic harm is often met with a mixture of confusion and profound betrayal. Whether you underwent a post-mastectomy reconstruction at a major center like Maine Medical Center in Portland or Northern Light Eastern Maine Medical Center in Bangor, or sought a cosmetic augmentation or mastopexy at a specialized plastic surgery practice in the Maine area, you were likely told that the materials used to support your body were safe, tested, and approved.
However, for many patients in Maine, the reality has been far different. Acellular dermal matrix (ADM), bioabsorbable scaffolds like GalaFLEX, and textured implants have been linked to a spectrum of complications ranging from severe infections and “red breast syndrome” to rare cancers like BIA-ALCL and BIA-SCC. At Attorney911, led by Managing Partner Ralph Manginello and Associate Attorney Lupe Peña, we represent women and families across Maine who have been victimized by defective medical devices. Our firm brings twenty-seven years of high-stakes litigation experience and a deep understanding of the federal regulatory failures that allowed these products into Maine operating rooms.
If you are experiencing complications or have received a diagnosis of BIA-ALCL or BIA-SCC in Maine, we are here to provide the educational resources and legal advocacy you deserve. You can reach our team at 1-888-ATTY-911 for a confidential, no-cost consultation.
Understanding the Devices: What Was Implanted in Your Body?
Many patients in Maine are surprised to learn that the products used in their breast surgeries often fall into categories that most people associate with hernia repair or general wound care. In both reconstructive and cosmetic procedures, surgeons frequently use “internal bra” techniques to provide structural support to the lower pole of the breast. This is achieved using one of three primary types of products.
Acellular Dermal Matrix (ADM)
ADM is a biologic material derived from donated human or animal skin. The “acellular” designation means that the cells have been stripped away, leaving a collagen scaffold that is intended to integrate with your own tissue. Common brands used in Maine facilities include AlloDerm (Allergan/AbbVie), Strattice, FlexHD (MTF Biologics), AlloMax (Becton Dickinson), and SurgiMend (Integra LifeSciences). While promoted as a natural solution, ADM in Maine surgeries has been associated with elevated infection rates and chronic inflammatory responses.
Bioabsorbable and Resorbable Scaffolds
These are synthetic scaffolds designed to be absorbed by the body over a set period, typically 12 to 24 months. The most prominent example is GalaFLEX, manufactured by Galatea Surgical (a Becton Dickinson subsidiary) and composed of poly-4-hydroxybutyrate (P4HB). Other examples include Phasix Mesh and DuraSorb. These products were cleared by the FDA for “soft tissue reinforcement” but never specifically for the unique and sensitive environment of the human breast.
Synthetic Surgical Mesh
Occasionally, permanent synthetic meshes—often made of polypropylene—are used off-label in Maine breast surgeries. These materials were originally designed for hernia repair and have long histories of causing complications when implanted in soft, glandular tissue.
Ralph Manginello and the team at Attorney911 have seen how these devices are marketed to Maine surgeons as essential tools for achieving better aesthetic results, often without disclosing the high rate of complications documented in independent medical literature. If you are unsure which device was used in your surgery, our firm can help you navigate the process of securing your operative reports and device identifiers. Call 888-ATTY-911 to discuss your situation with a team that understands the difference between biologic ADM and synthetic scaffolds.
The FDA Regulatory Failure: “The Potential for Harm in Maine”
One of the most distressing facts for patients in Maine is the nature of how these devices reached the market. Most of the ADM and scaffold products used in Maine were cleared through the FDA’s 510(k) pathway. Under 21 USC §360c and 21 CFR Part 807 Subpart E, the 510(k) pathway allows a manufacturer to market a device by showing it is “substantially equivalent” to a “predicate device” that is already on the market.
This process is a comparative inquiry, not a finding of safety or effectiveness. As Ralph Manginello often explains to our clients, 510(k) clearance is a regulatory shortcut. It allows a manufacturer to skip the rigorous clinical trials required for Premarket Approval (PMA) under 21 CFR Part 814. In many cases, the “predicate” device used to clear a breast mesh was actually a surgical suture or a hernia mesh—products never intended for use in a breast pocket.
The FDA explicitly addressed this gap in its November 9, 2023, letter to healthcare providers, which reached every major oncology and plastic surgery center in Maine. In that letter, the FDA stated: “The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.” The agency further clarified that “no surgical mesh products have been cleared or approved by the FDA for use in breast surgery.”
By citing 21 CFR §807.92, the manufacturers claimed substantial equivalence, but they failed to warn women in Maine that the products were being used “off-label” in a way that had never been clinically validated. Lupe Peña, who brings a background in insurance defense to our firm, knows how manufacturers use these regulatory nuances to attempt to shield themselves from liability. At Attorney911, we use these same regulations to build the case for failure to warn, as seen in our prosecution of complex institutional liability in cases like Bermudez v. Pi Kappa Phi, where we currently seek $10,000,000 for systemic failures in oversight. Maine patients deserve the same level of aggressive representation against medical device giants.
The Spectrum of Complications: From Infection to Cancer
For a woman in Maine, a complication from a breast procedure isn’t just a medical event—it is a disruption of her recovery and her life. These complications can present immediately after surgery or years later.
Red Breast Syndrome (RBS) and Sterile Inflammation
Red Breast Syndrome is a non-infectious, sterile inflammatory response specific to ADM. Peer-reviewed literature, such as that by Nguyen et al. (2019), suggests that this is an endotoxin-mediated response. Even after terminal sterilization, bacterial endotoxins (lipopolysaccharides) can remain on the matrix, triggering a host response. Patients in Maine often describe a persistent, bright red appearance of the breast that does not respond to antibiotics.
Surgical Site Infection and Sepsis
ADM more than doubles the risk of infection compared to reconstructions without it. The pooled odds ratio for infection is 2.7 (95% CI 1.1–6.4). In severe cases, this can lead to sepsis, a life-threatening systemic reaction. If you were treated for sepsis at a facility in Maine following a reconstruction, the device used may be the underlying cause.
BIA-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma
BIA-ALCL is a distinct T-cell lymphoma recognized by the World Health Organization. It is characterized as CD30-positive and ALK-negative. While primarily associated with textured surfaces, such as the recalled Allergan BIOCELL implants, the inflammatory environment created by mesh and scaffolds is a critical area of ongoing litigation. The Allergan recall in July 2019 followed findings that textured surfaces were six times more likely to cause this malignancy.
BIA-SCC: Breast Implant-Associated Squamous Cell Carcinoma
BIA-SCC is an even rarer and more aggressive epithelial tumor identified in the capsule around breast implants. The FDA issued a safety communication in September 2022 and updated it in March 2023, documenting cases that emerged seven to forty-two years after implantation.
Mechanical and Structural Failures
Bioabsorbable scaffolds like GalaFLEX are marketed to resorb within 18 to 24 months. However, many Maine patients report palpable mesh edges or scaffold “bottoming out” long after the resorption window. This can lead to permanent breast asymmetry, reconstruction failure, and the need for multiple revision surgeries.
Ralph Manginello and Lupe Peña emphasize that if you have experienced these or other tissue-reaction complications in Maine, you are not alone. Our firm is dedicated to ensuring that Maine survivors have access to the same level of technical and legal expertise as those in major metropolitan hubs. Contact us at 1-888-288-9911 for a free case evaluation.
Why Technical Expertise Matters in Maine Device Litigation
Defective medical device litigation is notoriously complex. Generalist personal injury firms in Maine may be capable of handling a car accident, but they often lack the substantive command of the federal preemption doctrine required to take on companies like Allergan or Becton Dickinson.
The manufacturers often rely on Riegel v. Medtronic, 552 U.S. 312 (2008), to argue that state-law claims are preempted. However, because products like GalaFLEX and AlloMax were cleared through the 510(k) pathway—and not through the rigorous PMA process—they do not enjoy the same level of federal protection. This distinction, established in Medtronic v. Lohr, 518 U.S. 470 (1996), is the key to holding these companies accountable in Maine.
Furthermore, we utilize the “parallel claim” exception to Riegel. We argue that the manufacturers violated existing federal requirements, such as those found in 21 CFR Part 803 regarding Medical Device Reporting (MDR). When a manufacturer fails to report adverse events—like the documented under-reporting alleged by whistleblower Dr. Hooman Noorchashm regarding GalaFLEX—they lose their shield against state-law negligence claims.
Ralph Manginello has been licensed since 1998 and is admitted to the United States District Court for the Southern District of Texas, where many of these national cases originate. Our current lead counsel role in Bermudez v. Pi Kappa Phi demonstrates our ability to litigate against thirteen distinct defendants in a single high-profile action. We bring that same institutional-liability focus to every Maine case we touch.
Maine Legal Landscape: Deadlines and Venue
For a resident of Maine, understanding the procedural path of a lawsuit is essential. If you file a defective device claim, your case may be heard in the U.S. District Court for the District of Maine, or it may be transferred to a Consolidated Multidistrict Litigation (MDL).
Statutes of Limitation in Maine
The statute of limitations is the deadline for filing your lawsuit. In Maine, the general statute of limitations for personal injury is six years, which is one of the more generous timelines in the United States. However, if your claim involves a medical malpractice component against a Maine healthcare provider, the deadline may be significantly shorter. Crucially, the “discovery rule” in Maine holds that the clock may not start until you reasonably should have discovered the link between the device and your injury. Because the FDA only issued its explicit labeling-update letter in November 2023, many women in Maine who had surgeries years ago are just now discovering their legal rights.
Venue and MDL Posture
If your case involves Allergan BIOCELL implants, it will likely be part of MDL No. 2921 in the District of New Jersey under Judge Brian R. Martinotti. Transitioning to an MDL allows for coordinated discovery and a set of “bellwether” trials—the first of which for surgical explants is currently scheduled for October 19, 2026. For GalaFLEX or Phasix cases, we are currently monitoring and participating in the first wave of state-court litigation in jurisdictions like Rhode Island, where the manufacturers are headquartered.
Our firm provides Maine residents with a bridge to these national legal battles. Lupe Peña, who is fluent in Spanish and conducts full client consultations without an interpreter, ensures that our outreach is inclusive of and accessible to Maine’s diverse patient population. Call our 1-888-ATTY-911 intake line to learn more about how Maine law applies to your unique medical history.
The Whistleblower Evidence: Dr. Hooman Noorchashm
At Attorney911, we believe in arming our Maine clients with the “insider” knowledge that defines a winning case. One of the most significant developments in recent years is the record of Dr. Hooman Noorchashm. A former Medical Director at Becton Dickinson (the manufacturer of GalaFLEX and Phasix), Dr. Noorchashm was terminated in 2022 after raising internal alarms about patient safety.
His allegations, filed in New Jersey court, include claims that breast cancer recurrences in BD’s clinical trials were withheld from the FDA. He has publicly warned surgeons that the “internal bra” use of these products is experimental and that the manufacturers lacked proper Investigational Device Exemption (IDE) authorization. For a reconstruction patient in Maine, this evidence is vital—it proves that the company knew about the risks and chose to prioritize market share over patient safety.
What to Do Now: Action Steps for Maine Patients
If you suspect your breast reconstruction or augmentation is failing due to a defective ADM, mesh, or scaffold in Maine, follow these steps immediately:
- Secure Your Records: Request your complete operative reports from your Maine surgical facility. Specifically, look for “UDI” or device implant stickers. These contain the brand, model, and lot number of the device.
- Preserve the Evidence: If you require revision surgery, instruct your Maine surgeon and the pathology lab to preserve the explanted mesh or tissue. This physical evidence is critical for testing endotoxin levels or identifying the failure mechanism.
- Document Symptoms: Keep a journal of redness, pain, fluid drainage, or asymmetric changes. Take photographs of any visible skin changes.
- Consult with Specialist Counsel: Defective device litigation requires a firm that can cite 21 CFR §803.10 and 21 CFR §814.39 with more precision than a generic marketing agency.
Our firm offers a no-cost, no-obligation consultation to any woman in Maine affected by these devices. We work on a contingency-fee basis, meaning you pay us nothing unless we recover compensation for you. Ralph Manginello’s 8.2 Avvo “Excellent” rating and Martindale-Hubbell Preeminent status are reflections of our commitment to quality service.
Frequently Asked Questions for Maine Residents
Is surgical mesh FDA-approved for breast surgery?
No. As the FDA stated in its November 2023 letter to Maine healthcare providers, the safety and effectiveness of mesh in breast procedures have not been determined. It is currently used “off-label.”
What if my mesh was bioabsorbable?
Even “resorbable” scaffolds like GalaFLEX can cause injury. If the product fails to resorb as advertised or triggers a chronic inflammatory response, you may still have a valid claim in Maine.
How much is a breast mesh lawsuit worth?
While every case is different, comparable mesh settlements in the transvaginal and pelvic sectors have resulted in billions of dollars in payouts. The BD/Bard hernia mesh settlement in October 2024 resolved roughly 40,000 claims for an estimated $1 billion or more.
Can I sue if I have BII (Breast Implant Illness)?
Yes. While BII is a clinical diagnosis based on systemic symptoms, we evaluate these cases based on the failure to warn and the manufacturer’s knowledge of immunological triggers.
Do I need a lawyer in Maine or where the company is located?
You need a lawyer with federal court access and experience in mass tort litigation. We represent clients across the country from our Texas-based offices, and our federal court admission allows us to handle device cases originating in Maine.
Hablamos español?
Sí, hablamos español. La abogada Lupe Peña realiza consultas completas en español para asegurar que nuestras clientes en Maine entiendan sus derechos legales sin barreras lingüísticas.
A Legacy of Service and Results
Choosing a law firm is a significant decision. Ralph Manginello is not just a trial attorney; he is a member of the Pro Bono College of the State Bar of Texas, a recognition for those who exceed the state’s aspirational service goals. Our firm’s Birdeye ratings of 4.9 of 5.0 stars across hundreds of reviews reflect a history of client trust.
We understand the specific challenges faced by the Maine community—from the high-volume medical centers in Portland to the rural access points in the North. We have watched our high-profile litigation in Bermudez v. Pi Kappa Phi force institutional change, including the shutdown of a fraternity chapter after our $10,000,000 filing. We bring that same aggressive, persistent pursuit of justice to every defective device case we handle for Maine survivors.
If you are a breast cancer survivor whose healing has been halted by a defective ADM, or a cosmetic patient dealing with the fallout of a scaffold “internal bra,” your voice matters. Do not let a manufacturer’s “predicate creep” or regulatory shortcuts define your future health.
When you are ready to talk, we are here to listen. You can contact us 24/7 at 1-888-ATTY-911 or through our online platform at attorney911.com. We serve the entire Maine region, including Portland, Lewiston, Bangor, and South Portland, with the technical authority and compassionate medical authority your case demands.
Past results are no guarantee of future outcomes, but our dedication to the Maine community is absolute. Every case has unique facts, and we invite you to share yours with us for a thorough and honest evaluation. Your recovery—physically, emotionally, and financially—is our priority. Contact Attorney911 today.
